CompletedNot Applicable

Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy

United States273 participantsStarted 2012-10-04

Plain-language summary

This research trial studies metabolomic and other molecular profiling to identify predictive biomarkers for radiation toxicity and survival in patients with lung or brain cancers receiving radiation therapy. Studying samples of blood, urine, and tissue from patients with lung or brain cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer and predict which patients are at higher risk for developing radiation side effects and how well patients will respond to radiation treatment.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Consultation with the Radiation Oncology department of the Ohio State University (OSU) Comprehensive Cancer Center * The following diagnoses will be included: malignant neoplasm of the brain; primary malignant neoplasm of trachea bronchus and lung; primary malignant neoplasm of the cervix uteri and primary malignant neoplasm the prostate Exclusion Criteria: * Being an inmate

What they're measuring

Potential predictive biomarkers for the development of radiation pneumonitis for lung cancer patients

Timeframe: Baseline

Potential predictive biomarkers for the development of radiation necrosis for brain cancer patients

Timeframe: Baseline

Trial details

NCT IDNCT02259218

SponsorOhio State University Comprehensive Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-17

View on ClinicalTrials.gov More Adult Brain Tumor trials